BioPharma Resources

Drug Trial Radar · NCT05406401

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Cyclophosphamide, Doxorubicin, and Prednisone Plus Rituximab or Rituximab Biosimilar (Truxima) (R-CHP) in Participants With Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-007)

A Multicenter, Open-label, Phase 2 Dose Escalation and Confirmation, and Efficacy Expansion Study of Zilovertamab Vedotin (MK-2140) in Combination With R-CHP in Participants With DLBCL (waveLINE)

Last checked: Nov 19, 2026Latest source record: Oct 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 14, 2022

Primary completion

Apr 26, 2029

Study completion Apr 26, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Jun 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study consists of a dose escalation/confirmation phase and an efficacy expansion phase. The dose escalation/confirmation phase is to determine the safety and tolerability and establish a preliminary recommended Phase 2 dose (RP2D) of zilovertamab vedotin when administered in combination with R-CHP in participants with DLBCL who have received no prior treatment for their disease. The efficacy expansion phase is to determine the efficacy of the RP2D of zilovertamab vedotin when administered in combination with R-CHP in participants with DLBCL who have received no prior treatment for their disease.

Conditions

  • Lymphoma, Large B-Cell, Diffuse (DLBCL)

Interventions

  • Zilovertamab VedotinBiological

    IV infusion

  • CyclophosphamideDrug

    IV infusion

  • DoxorubicinDrug

    IV infusion

  • RituximabBiological

    IV infusion

  • Rituximab BiosimilarBiological

    IV infusion

  • PrednisoneDrug

    IV or oral administration (per local guidelines)

  • PrednisoloneDrug

    IV or oral administration (per local guidelines)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Dose-limiting Toxicities (DLTs) in Cycle 1Time frame: Cycle 1 (up to 21 days)
  2. Number of Participants Who Experienced At Least One AETime frame: Up to approximately 8 months
  3. Number of Participants Who Discontinued Study Treatment Due to an AETime frame: Up to approximately 5.5 months
  4. Complete Response Rate (CRR) per Lugano Response CriteriaTime frame: Up to approximately 60 months

Locations

22 sites in 7 countries. Site status is shown where the registry gives one.

  • BC Cancer Victoria-Clinical Trials Unit ( Site 0105)

    Victoria, British Columbia, Canada

  • William Osler Health System ( Site 0106)

    Toronto, Ontario, Canada

  • Hopital du Sacre-Coeur de Montreal ( Site 0108)

    Montreal, Quebec, Canada

  • Hadassah Medical Center ( Site 0401)

    Jerusalem, Israel

  • Sheba Medical Center-Hemato Oncology ( Site 0400)

    Ramat Gan, Israel

  • Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare -Azienda Ospedaliera Nazionale SS. Ant

    Alessandria, Italy

  • Fondazione Policlinico Universitario Agostino Gemelli-ISTITUTO DI EMATOLOGIA ( Site 0306)

    Rome, Lazio, Italy

  • Ospedale San Raffaele-Unità Linfomi ( Site 0305)

    Milan, Lombardy, Italy

  • Az. Osp. Ospedali Riuniti VILLA SOFIA-CERVELLO-EMATOLOGIA I ( Site 0307)

    Palermo, Sicily, Italy

  • Azienda Ospedaliera Universitaria Careggi-SOD Ematologia ( Site 0308)

    Florence, Tuscany, Italy

  • Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumat-Oddiał Hematologii Ogólnej ( Site 0503)

    Lodz, Łódź Voivodeship, Poland

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Kilinka Onkologii I Hematologii ( Site

    Warsaw, Masovian Voivodeship, Poland

  • Uniwersyteckie Centrum Kliniczne-Klinika Hematologii i Transplantologii ( Site 0504)

    Gdansk, Pomeranian Voivodeship, Poland

  • Narodowy Instytut Onkologii - Oddzial w Gliwicach ( Site 0505)

    Gliwice, Silesian Voivodeship, Poland

  • Seoul National University Hospital ( Site 0201)

    Seoul, South Korea

  • Samsung Medical Center ( Site 0200)

    Seoul, South Korea

  • Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 0700)

    Madrid, Spain

  • HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Hematology ( Site 0704)

    Seville, Andalusia, Spain

  • Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 0703)

    L'Hospitalet Del Llobregat, Barcelona, Spain

  • Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 0801)

    Ankara, Turkey (Türkiye)

  • Trakya University ( Site 0805)

    Edirne, Turkey (Türkiye)

  • Mega Medipol-Hematology ( Site 0808)

    Stanbul, Istanbul, Turkey (Türkiye)

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.